TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06561347: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Sponsor: Massachusetts General Hospital · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 65 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT06561347 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06561347 Rescue Dossier →